Chronic myeloid leukaemia: the evolution of gene‐targeted therapy

Chronic myeloid leukaemia (CML) was the first human cancer linked to an acquired chromosomal abnormality, subsequently shown to be a reciprocal translocation between chromosomes 9 and 22. The resulting fusion gene product, BCR‐ABL, was shown to be the causative agent of the disease. CML has an incid...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medical journal of Australia 2008-09, Vol.189 (5), p.277-282
1. Verfasser:	Joske, David J L
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Australia Benzamides Binding sites Biological and medical sciences Bone marrow Cancer therapies Chromosomes Drug Approval Fusion Proteins, bcr-abl - antagonists & inhibitors Fusion Proteins, bcr-abl - genetics General aspects Health services administration Hematologic and hematopoietic diseases Hematologic diseases Hematology Humans Imatinib Mesylate Interferon Kinases Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Piperazines - therapeutic use Polymerase chain reaction Pyrimidines - therapeutic use Signal transduction United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!